Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P. Tobin, Martin D. McCarter, Dasha T. Cogswell et al.|Clinical Cancer Research|2022Cited by 89
Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma.Martin D. McCarter, William A. Robinson, Richard P. Tobin et al.|Journal of Clinical Oncology|2021Cited by 4
Targeting MDSCs using ATRA: a phase I/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanomaRichard P. Tobin, Martin McCarter, Dasha T. Cogswell et al.|Research Square|2021Cited by 1
Supplementary table 2 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P. Tobin, Martin D. McCarter, Dasha T. Cogswell et al.|Unknown|2023Cited by 0
Supplementary Figure S1 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P. Tobin, Martin D. McCarter, Dasha T. Cogswell et al.|Unknown|2023Cited by 0